Target intelligence / Profile preview

Homeobox protein Nkx-2.1 (NKX2-1)

Target
NKX2-1
Molecular classification
Transcription factor, Homeobox protein, DNA-binding protein, Regulatory protein
01

Overview

Homeobox protein Nkx-2.1 (NKX2-1), also known as thyroid transcription factor 1 (TTF-1), is a nuclear transcription factor encoded by the NKX2-1 gene. It regulates gene expression critical for the development and function of the thyroid, lung, and brain, controlling processes such as morphogenesis, cell differentiation, and the synthesis of key functional proteins. In the thyroid, it orchestrates the production of hormones by regulating thyroglobulin and thyrotropin receptor genes. In the lung, it directs surfactant protein expression, essential for respiratory function, and is vital for proper fetal organ development. NKX2-1 is a lineage-specific marker commonly used in pathology to identify tumors of the thyroid and lung. Mutation or altered expression of NKX2-1 is implicated in several diseases, including congenital hypothyroidism, respiratory distress syndrome, benign hereditary chorea, and various cancers, most notably lung adenocarcinoma and thyroid cancer[1][2][3][4][5][6][7][8][9].

Other names
Thyroid transcription factor 1TTF-1TTF1NK2 homeobox 1TITF1NKX2AT/EBPThyroid nuclear factor 1Thyroid-specific enhancer-binding proteinNK-2 homolog ABCHBHCNMTC1TEBP
02

Mechanism of action

Gene therapy approaches: re-expression of NKX2-1 in deficient cancer cells induces cell death by apoptosis and necrosis. Transcriptional regulation of downstream genes (e.g., thyroglobulin, thyroperoxidase, surfactant proteins).

03

Biological functions

Regulation of gene expressionDevelopment of lung, thyroid, and brain structuresCell differentiationMorphogenesisRegulation of surfactant production in lungRegulation of thyroid hormone synthesisNeural development (interneuron migration)
04

Disease associations

Cancer (lung adenocarcinoma, thyroid cancer, small cell carcinoma)Congenital hypothyroidismNeonatal respiratory distress syndromeBenign hereditary choreaChoreoathetosisInterstitial lung disease
05

Safety considerations

NKX2-1 mutations are associated with developmental defects in lung, thyroid, and brainLoss of function may lead to severe and sometimes fatal lung disease in infantsTherapeutic challenges in modulating a key developmental transcription factor without off-target effects
06

Interacting drugs

Potential indirect regulation by gene therapy vectors (adenoviral NKX2-1)
07

Biomarkers

Immunohistochemical marker for tumors of lung and thyroid origin (TTF-1 IHC staining)Used to distinguish primary lung or thyroid tumors in pathology

Beyond the preview

Go deeper on Homeobox protein Nkx-2.1 (NKX2-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Homeobox protein Nkx-2.1 (NKX2-1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call